Given their roles in promoting pro-tumor inflammation, tumor progression, and cell migration and trafficking, combining pathway-specific inhibitors with next-generation CAR T-cell therapy or BTK inhibitors may offer enhanced therapeutic efficacy in ABC cases characterized by the activation of multiple signaling pathways. This evidence concerns the gene BTK and neoplasm.